Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesSpyGlass Pharma, Inc.

SpyGlass Pharma, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
34.97 USD 0.79 ( 2.31%)
Last update at 2026-11-11T21:00:00Z
VOLUME
77464
Market Cap
968.65M

Momentum Score

…

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
33.24
Low
35.53
High
52 Week Price Range
17.06
Low
32.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
34.18
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.02
ROE
-67.71%
Net Debt
-94.78M
ROCE
-37.16%
Diluted EPS TTM
-1.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax -39.87M -29.16M -13.32M
Net income -39.87M -29.16M -13.32M
Selling general administrative 12.20M 7.08M 4.27M
Gross profit -0.61M - -
Reconciled depreciation 0.61M 0.27M 0.12M
Ebit -39.87M - -
Ebitda -39.26M - -
Depreciation and amortization 0.61M - -
Operating income -41.45M -27.06M -14.23M
Other operating expenses 41.45M - -
Tax provision 0.00M 0.00M 0.00M
Interest income 3.11M 1.32M 0.91M
Net interest income 3.11M 1.32M 0.91M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 40.84M 27.06M 14.23M
Cost of revenue 0.61M - -
Total other income expense net 1.58M -3.42M -
Net income from continuing ops -39.87M -29.16M -13.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 115.87M 23.32M 41.15M
Other current assets 0.90M 0.23M -
Total liab 214.70M 83.79M 74.13M
Total stockholder equity -98.84M -60.47M -32.99M
Other current liab 5.89M 4.09M 0.34M
Capital stock 0.00M 0.00M 0.00M
Retained earnings -104.73M -64.86M -35.70M
Cash 96.36M 16.27M 15.85M
Total current liabilities 8.58M 7.79M 1.59M
Net debt -94.78M - -
Short long term debt total 1.58M - -
Other stockholder equity 5.89M - -
Total current assets 108.77M 17.41M 40.61M
Short term investments 11.08M 0.00M 24.47M
Net receivables 0.43M - -
Accounts payable 2.70M 1.98M 0.64M
Non currrent assets other 3.21M 0.45M 0.09M
Non current assets total 7.10M 5.91M 0.53M
Capital lease obligations 1.58M 3.90M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Investments -11.01M 24.25M -20.27M
Total cashflows from investing activities -11.79M - -
Total cash from financing activities 124.58M 0.18M 39.77M
Net income -39.87M -29.16M -13.32M
Change in cash 80.09M 0.42M 7.01M
Begin period cash flow 16.27M 15.85M 8.84M
End period cash flow 96.36M 16.27M 15.85M
Total cash from operating activities -32.70M -22.03M -12.28M
Issuance of capital stock 127.34M 0.00M 40.01M
Depreciation 0.61M 0.27M 0.12M
Change to account receivables -0.01M - -
Sale purchase of stock -1.45M 0.00M -
Other cashflows from financing activities 125.86M - -
Capital expenditures 0.79M 1.99M 0.22M
Change in working capital 2.45M 1.34M 0.11M
Stock based compensation 2.79M 1.49M 0.87M
Other non cash items 1.32M 0.62M -0.07M
Free cash flow -33.49M -24.02M -12.49M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
SGP
SpyGlass Pharma, Inc.		 0.79
2.31%		 34.97 - - - 4.13
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

15326 Alton Parkway, Irvine, CA, United States, 92618

949 284 6904

https://www.spyglasspharma.com

76

Name Title Year Born
Dr. Malik Y. Kahook M.D. Co-Founder, President, Chief Medical Officer & Executive Chairman 1975
Mr. Patrick H. Mooney CEO & Director 1974
Dr. Chetan Pujara Ph.D. Chief Research & Development Officer 1970
Mr. Glenn Sussman Co-founder & Chief Technology Advisor 1964
Dr. Jean-Frederic Viret Ph.D. Chief Financial Officer 1966
Mr. James Robert Dennewill Jr. Chief Operating Officer 1981
Ms. Shannon Trevino J.D. General Counsel NA
Mr. Mike Pinder Vice President of Marketing NA
Ms. Rachel Gilette Vice President of Human Resources NA
Mr. Paul Yoo O.D. Senior Vice President of Clinical Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…